Biden team to help AstraZeneca find US plant to produce vaccine

Johnson & Johnson has taken over production of its vaccine at a Emergent BioSolutions facility in Baltimore, which was previously manufacturing J&J and AstraZeneca doses.

President Joe Biden’s administration is working with AstraZeneca Plc to find new manufacturing capacity in the U.S. after the company agreed to abandon a Baltimore Covid-19 vaccine plant that will focus exclusively on making doses for Johnson & Johnson. The talks are the latest development after an error at the Emergent BioSolutions Inc. facility — in which ingredients for the two companies’ vaccines were mixed up — led to a batch of 15 million doses worth of drug substance being spoiled. J&J announced Saturday that it had taken over production of its vaccine at the Emergent facility, which was manufacturing J&J and AstraZeneca doses. The Department of Health and Human Services worked with AstraZeneca to shift production from the plant.